All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Evotec AG has out-licensed its lead monoamine oxidase type B (MAO-B) product for Alzheimer's disease in a $830 million deal with Roche AG, taking $10 million up front, followed by short-term clinical milestones of $170 million and the balance to come in commercial milestones.